Share

Appointment of Malte Peters as EORTC Strategic Alliance Officer

It is with great pleasure that we announce that Malte Peters, M.D. has joined EORTC as Strategic Alliance Officer (SAO), effective 1 February 2024. The SAO is responsible for building and managing the relationships between EORTC and specific stakeholders. The objective is to improve the understanding and the capabilities of the organisation for new partnerships.

“In my role, I will build and manage the relationships between EORTC and various stakeholders. The goal is to help all stakeholders understand the numerous and outstanding capabilities of EORTC.”, Malte Peters.

Improving access to new agents:

  • Establishing and maintaining relationships with partners to strengthen existing relationships and develop new ones.
  • Understanding the needs and goals of each organisation, and working to identify opportunities for collaboration that will benefit both parties.
  • Identifying and pursuing new areas for growth and expansion of new and existing alliances.
  • Stay abreast of industry trends and developments and share relevant insights with internal and external stakeholders.
  • Developing directions for implementing the alliance, including timelines and action items for all parties involved.
  • Monitoring the progress of each alliance to ensure that goals are being met and any hiccups in the process are being addressed.
  • Reporting on activity progress against agreed-upon milestones, and course correct as necessary to ensure successful outcomes.

About Malte Peters

SAO

Malte Peters

Between 2017 and 2022, Malte was the Chief Research and Development Officer (CR&DO) of MorphoSys AG. In this function, he was responsible for the development of all clinical, research, and pre-clinical programs. During his tenure, he was instrumental in the global approval of Monjuvi, an anti-CD19 monoclonal antibody in combination with Lenalidomide, for patients with second line or higher diffuse large B Cell lymphoma (DLBCL), as well as for the acquisition of Pelabresib, a BET inhibitor being developed in combination with Ruxolitinib for the treatment of patients with front-line myelofibrosis.

Before joining MorphoSys AG, Malte was Global Head of Clinical Development at Sandoz Biopharmaceuticals. In this function, he was responsible for all clinical development aspects of several regulatory submissions in the EU and the US leading to approval of biosimilars of Enbrel and Rituximab.

Before that, he was Vice President and Clinical and Site Head for Basel, East Hanover, and Shanghai for Oncology Translational Medicine at Novartis. Prior to his 13 years at Novartis, he had leadership roles at Amgen, Merck KgaA, and Micromet.

Malte trained in internal medicine, gastroenterology, and oncology in Germany and in the United States.

Back to news list

Related News

  • We are pleased to announce the release of the EORTC 2023 Annual Report

  • Dr Denis Lacombe, EORTC CEO, appointed stakeholder co-chair of ACT EU advisory group

  • Clinical Trials Day 2024: a Q&A on pragmatic clinical trials

  • EORTC/EMA workshop suggests an international way forward for treatment optimisation studies

  • EORTC’s Participation at the ESTRO Congress 2024

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023